# A 6 Month Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older

> **NCT01067105** · PHASE3 · COMPLETED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 824 (actual)

## Conditions studied

- Perennial Allergic Rhinitis

## Interventions

- **DRUG:** ciclesonide HFA 160 μg

## Key facts

- **NCT ID:** NCT01067105
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 824 (ACTUAL)
- **Last updated:** 2012-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01067105

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01067105, "A 6 Month Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01067105. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*